Parenteral administration of GM1 ganglioside to presenile Alzheimer patients

Acta Neurol Scand. 1990 Jan;81(1):48-53. doi: 10.1111/j.1600-0404.1990.tb00930.x.

Abstract

The pharmacokinetic parameters of GM1 ganglioside were examined in 16 patients (mean age 64 +/- 5 years) with Alzheimer's disease. The ganglioside was given intramuscularly and subcutaneously. The maximum GM1 blood level was reached after 48-72 h, the subcutaneous route leading to the highest blood levels, but the individual variability was relatively large. When 100 mg GM1 ganglioside was given daily for a week, maximum serum values of 15 to 20 mumol/l were found in 3 patients. The elimination half-life from serum was 60-75 h.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy*
  • G(M1) Ganglioside / administration & dosage
  • G(M1) Ganglioside / pharmacokinetics*
  • G(M1) Ganglioside / therapeutic use
  • Humans
  • Injections, Intramuscular
  • Injections, Subcutaneous
  • Middle Aged

Substances

  • G(M1) Ganglioside